Satellos Bioscience (MSLE) highlights SAT-3247 at key investor conferences

Rhea-AI Filing Summary

Satellos Bioscience Inc., a clinical-stage biotechnology company focused on restoring natural muscle repair and regeneration in degenerative muscle diseases, will present at several upcoming investor conferences. Management is scheduled to participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference, the TD Cowen 46th Annual Health Care Conference, and the Leerink Partners Global Healthcare Conference, through presentations and investor meetings. Live webcasts of the presentations will be accessible on the company’s website in the Investors section. The company highlights its lead oral small molecule candidate SAT-3247, which targets AAK1 and is being developed as a potential disease-modifying treatment for Duchenne muscular dystrophy, supported by ongoing Phase 2 studies in adult and pediatric participants.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934

For the month of February 2026

(Commission File No. 001-43107)

SATELLOS BIOSCIENCE INC.

(Translation of registrant’s name into English)

Royal Bank Plaza, South Tower, 200 Bay Street, Suite 2800

Toronto, Ontario, ON M5J 2J3

(Address of registrant’s principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ¨               Form 40-F x

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (1): ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (7): ¨

DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K

Exhibit		Description
99.1		News Release dated February 17, 2026. Satellos to Participate in Upcoming Investor Conferences.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Satellos Bioscience Inc.

	By:	/s/ Elizabeth Williams, CPA, CA
	Name:	Elizabeth Williams, CPA, CA
	Title:	Chief Financial Officer

Date: February 19, 2026

Exhibit 99.1

Satellos to Participate in Upcoming Investor Conferences

TORONTO, Feb. 17, 2026 (BUSINESS WIRE) — Satellos Bioscience Inc. (Nasdaq: MSLE, TSX: MSCL) (“Satellos” or the “Company”), a clinical-stage biotechnology company focused on restoring natural muscle repair and regeneration in degenerative muscle diseases, today announced that management will present at and participate in the following investor conferences:

Oppenheimer 36^th Annual Healthcare Life Sciences Conference

Date: Thursday, February 26, 2026

Format: Presentation

Time: 10:40 a.m. – 11:10 a.m. ET

Location: Virtual

TD Cowen 46th Annual Health Care Conference

Date: Tuesday, March 3, 2026

Format: Presentation

Time: 1:10 – 1:40 p.m. ET

Location: Boston, MA

Leerink Partners Global Healthcare Conference

Date: March 8-11, 2026
Location: Miami, FL

The presentations will be available via live webcast on the Events and Presentations page in the Investors section of the Company’s website.

Members of the Satellos leadership team will also be available for one-on-one investor meetings during the conferences.

ABOUT SAT-3247

SAT-3247 is a proprietary, oral, small molecule drug candidate being developed by Satellos as a novel approach to regenerating skeletal muscle lost in Duchenne muscular dystrophy (DMD) and other degenerative muscle diseases or injury conditions. Satellos is advancing SAT-3247 as a potential treatment for DMD that is independent of dystrophin and applicable regardless of exon mutation status, with ongoing Phase 2 clinical studies, including TRAILHEAD, an open-label study in adult participants, and BASECAMP, a global, randomized, placebo-controlled study in pediatric participants.

ABOUT SATELLOS BIOSCIENCE INC.

Satellos is a clinical-stage drug development company focused on restoring natural muscle repair and regeneration in degenerative muscle diseases. Through its research, Satellos has developed SAT-3247, a first-of-its-kind, orally administered small molecule drug designed to address deficits in muscle repair and regeneration. SAT-3247 targets AAK1, a key protein that Satellos has identified as capable of helping restore muscle stem-cell signaling, a process that is disrupted in DMD. By addressing the loss of dystrophin-dependent cues, SAT-3247 may re-establish the signals that support effective muscle regeneration. SAT-3247 is currently in clinical development as a potential disease-modifying treatment, initially for DMD. Satellos is also working to identify additional muscle diseases or injury conditions where restoring muscle repair and regeneration may have therapeutic benefit and represent future clinical development opportunities. For more information, visit www.satellos.com.

CONTACTS

Investors: Liz Williams, CFO, ir@satellos.com
Media: Emily Williams, Senior Director of Communications, media@satellos.com

FAQ

What investor conferences will Satellos Bioscience (MSLE) attend in early 2026?

Satellos will join three healthcare investor conferences, providing presentations and meetings. These are the Oppenheimer 36th Annual Healthcare Life Sciences Conference, the TD Cowen 46th Annual Health Care Conference, and the Leerink Partners Global Healthcare Conference across virtual, Boston, and Miami locations.

When will Satellos Bioscience (MSLE) present at the Oppenheimer healthcare conference?

Satellos is scheduled to present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Thursday, February 26, 2026. The presentation will run from 10:40 a.m. to 11:10 a.m. and will be available via live webcast through the company’s investor website section.

What is Satellos’ lead drug candidate SAT-3247 and what disease is it targeting?

SAT-3247 is an oral small molecule drug candidate aimed at regenerating skeletal muscle in Duchenne muscular dystrophy. It targets AAK1 to help restore disrupted muscle stem-cell signaling and is being developed as a potential disease-modifying treatment with ongoing Phase 2 clinical studies.

How can investors access Satellos Bioscience (MSLE) conference presentations?

Investors can access Satellos’ conference presentations via live webcasts hosted on the Events and Presentations page in the Investors section of its website. This provides remote access to scheduled talks and updates shared by the company’s leadership team during the conferences.

What Phase 2 clinical studies are evaluating Satellos’ SAT-3247 program?

SAT-3247 is being evaluated in two Phase 2 studies for Duchenne muscular dystrophy. TRAILHEAD is an open-label study in adult participants, while BASECAMP is a global, randomized, placebo-controlled trial in pediatric participants designed to assess its disease-modifying potential.

Is SAT-3247 intended to work regardless of DMD exon mutation status?

SAT-3247 is being advanced as a potential Duchenne muscular dystrophy treatment that is independent of dystrophin and applicable regardless of exon mutation status. By targeting AAK1, it aims to re-establish muscle regeneration signals that are disrupted across different underlying DMD mutations.

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 EXHIBIT 99.1 7.4 KB